Gene Editing Market Analysis

Gene Editing Market Analysis

Based on technology, the market is divided into Zinc Finger Nucleases (ZFNs), CRISPR/Cas9, and TALENs, others. Among them, the CRISPR/Cas9 segment is expected to account for around 15.6% CAGR through 2030. This technological segment is simple, easy to use, and inexpensive compared to other techniques. Increasing demand for CRISPR/Cas9 for the investigation of genome to identify genetic disorders and its drug discovery will increase the opportunity of gene editing market segment.
 

CRISPR technology can be used for the treatment of cancer through gene-editing technology. Key market players such as Caribou Biosciences, Takara Bio, Thermo Fisher Scientific are focusing on their research and development activities for adapting innovations in the CRISPR/Cas9 technology.
 

Based on application, the market is segmented into animal genetic engineering, cell line engineering, and plant genetic engineering as well as others. Among these, the cell line engineering market accounted for over USD 2.2 billion in 2021. Cell-line engineering is widely used for stem cell based-cell therapy treatment.
 

Rapid development and advancement of genome editing technologies have enabled introduction of genetic changes into induced pluripotent stem cells (iPSCs) along with corrections of disease-causing genetic mutations. Recent adaptation and advancement in editing techniques including Zinc Finger Nucleases (ZFNs), CRISPR/Cas, and TALENs have made cell engineering cheaper and easy.
 

The market based on end-user is segmented into contract research organizations (CROs), biotech and pharma companies, and research institutes. The biotech and pharma companies segment accounted for over 45.5% market share in 2021. Growing focus on development of new gene editing technologies by various biotechnology companies will increase the segmental growth.
 

For instance, Horizon Discovery aimed to create genome editing tool with advanced technology for accurate and efficient functional genes. One of the products launched by the company includes Edit-R algorithm CRISPR guide RNAs to edit the targeted gene. In recent years, technology advancements have enabled the market players to transform gene editing tools that are efficient for the treatment of a genetic disorders.
 

North America captured around 38% of the market share in 2021 and is expected to grow significantly during the forecast years due to the rise in number of rare diseases in the U.S. and Canada. According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases affecting between 25 and 30 million Americans. Therefore, the demand for development of drugs to cure rare diseases increases by adaption of new gene editing tools and technologies. Also, presence of leading industry players in North America will foster the gene editing market growth.